Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: Feasibility study

Eva M. Sevick-Muraca, Ruchi Sharma, John C. Rasmussen, Milton V. Marshall, Juliet A. Wendt, Hoang Q. Pham, Elizabeth Bonefas, Jessica P. Houston, Lakshmi Sampath, Kristen E. Adams, Darlene Kay Blanchard, Ronald E. Fisher, Stephen B. Chiang, Richard Elledge, Michel E. Mawad

Research output: Contribution to journalArticle

246 Scopus citations

Abstract

Purpose: To prospectively demonstrate the feasibility of using indocyanine green, a near-infrared (NIR) fluorophore at the minimum dose needed for noninvasive optical imaging of lymph nodes (LNs) in breast cancer patients undergoing sentinel lymph node mapping (SLNM). Materials and Methods: Informed consent was obtained from 24 women (age range, 30-85 years) who received intradermal subcutaneous injections of 0.31-100 μg indocyanine green in the breast in this IRB-approved, HIPAA-compliant, dose escalation study to find the minimum microdose for imaging. The breast, axilla, and sternum were illuminated with NIR light and the fluorescence generated in the tissue was collected with an NIR-sensitive intensified charged-coupled device. Lymphoscintigraphy was also performed. Resected LNs were evaluated for the presence of radioactivity, blue dye accumulation, and fluorescence. The associations between the resected LNs that were fluorescent and (a) the time elapsed between NIR fluorophore administration and resection and (b) the dosage of NIR fluorophores were tested with the Spearman rank and Pearson product moment correlation tests, respectively. Results: Lymph imaging consistently failed with indocyanine green microdosages between 0.31 and 0.77 μg. When indocyanine green dosages were 10 μg or higher, lymph drainage pathways from the injection site to LNs were imaged in eight of nine women; lymph propulsion was observed in seven of those eight. When propulsion in the breast and axilla regions was present, the mean apparent velocities ranged from 0.08 to 0.32 cm/sec, the time elapsed between "packets" of propelled fluid varied from 14 to 92 seconds. In patients who received 10 μg of indocyanine green or more, a weak negative correlation between the fluorescence status of resected LNs and the time between NIR fluorophore administration and LN resection was found. No statistical association was found between the fluorescence status of resected LNs and the dose of NIR fluorophore. Conclusion: NIR fluorescence imaging of lymph function and LNs is feasible in humans at microdoses that would be needed for future molecular imaging of cancer-positive LNs.

Original languageEnglish (US)
Pages (from-to)734-741
Number of pages8
JournalRadiology
Volume246
Issue number3
DOIs
StatePublished - Mar 1 2008

    Fingerprint

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Sevick-Muraca, E. M., Sharma, R., Rasmussen, J. C., Marshall, M. V., Wendt, J. A., Pham, H. Q., Bonefas, E., Houston, J. P., Sampath, L., Adams, K. E., Blanchard, D. K., Fisher, R. E., Chiang, S. B., Elledge, R., & Mawad, M. E. (2008). Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: Feasibility study. Radiology, 246(3), 734-741. https://doi.org/10.1148/radiol.2463070962